

Mahreen Chaudhry Hoda

PATENT ATTORNEY



EXPERTISE

Mahreen's industry experience and her time in the US Patent Office allow her a unique perspective of being able to see applications from many vantages. With Elmore Law Group since 2007, she drafts and prosecutes patent applications specializing in biotechnology and pharmaceutical technology areas. Mahreen also excels at instructing and collaborating with foreign associates on prosecution of foreign patent applications. She works with clients to build a patent portfolio development strategy and then helps them realize their goals.

PATENT LAW EXPERIENCE

Mahreen has meaningful experience with the Patent Law Office and in industry. As Senior Patent Agent at Critical Therapeutics, Inc., a biopharmaceutical company focused on the development of products for inflammatory disease located in Lexington, Massachusetts, she was responsible for managing the company's patent portfolio including expanding the portfolio from about ten patent families to nearly fifty patent families. Prior to working at Critical Therapeutics, Mahreen was a Patent Examiner at the U.S. Patent and Trademark Office in an organic chemistry group (Art unit 1623 — organic chemistry and enzyme assays).

PREVIOUS POSITIONS

Prior to joining Elmore Patent Law Group, Mahreen was Senior Patent Agent at Critical Therapeutics, Inc. She also worked as a Patent Examiner with the U.S. Patent and Trademark Office.

Education

- J.D., Suffolk University Law School, Boston, MA
- M.S. Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA
- B.A. Psychology, Pre-Med; University of Virginia, Charlottesville, VA

Bar Admissions

- Bar of the Commonwealth of Massachusetts (2008)
- Bar of the United States Patent and Trademark Office

Professional Associations

Boston Patent Law Association

Publications

- Chaudhry, M., Sundaram, S., Gennings, C., Carter, H. and Gewirtz, D. A. (2001). The Vitamin D₃ analog ILX 23-7553 enhances the response to adriamycin and irradiation in MCF-7 breast tumor cells. *Cancer Chemotherapy and Pharmacology*, 47(5):429-36.
- Sundaram, S., Chaudhry, M., Reardon, D. and Gewirtz, D. A. (2000). EB 1089 enhances the antiproliferative and apoptotic effects of adriamycin in MCF-7 breast tumor cells. *Breast Cancer Research and Treatment*, 63(1):1-10.